Literature DB >> 18190974

A screening method for identifying disruptions in interferon signaling reveals HCV NS3/4a disrupts Stat-1 phosphorylation.

Karla J Helbig1, Evelyn Yip, Erin M McCartney, Nicholas S Eyre, Michael R Beard.   

Abstract

UNLABELLED: Viruses have evolved mechanisms to inhibit the innate immune response to infection. The aim of this study was to develop an efficient screening method to identify viral proteins and their ability to block Jak-Stat signaling using hepatitis C virus (HCV) as an example. The 2FTGH cell assay system was used in combination with transient transfection of HCV proteins in this study. Using 1000U/ml IFN and 30mM 6-TG to treat 2FTGH cells, it was established that transient protein expression in this cell system yielded 39% and 0% cell survival for the positive (HPV E7) and negative controls (GFP expression) respectively. Transient expression of HCV Core-p7 resulted in 22% cell survival, consistent with previous reports, while expression of the HCV serine protease NS3/4a resulted in 54% cell survival. NS3/4a was subsequently shown to inhibit phosphorylation of Stat-1 at the serine residue 727.
CONCLUSION: the 2FTGH cell assay system can be adapted for transient screening to examine the ability of viral proteins or other potential inhibitors to block the Jak-Stat signaling pathway. We show that HCV NS3/4a is able to block this pathway at the stage of Stat-1 serine 727 phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18190974     DOI: 10.1016/j.antiviral.2007.11.008

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  9 in total

Review 1.  Macrophages in hepatitis B and hepatitis C virus infections.

Authors:  Mathis Heydtmann
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

2.  Programmed death-1 affects suppressor of cytokine signaling-1 expression in T cells during hepatitis C infection.

Authors:  Ashley D Frazier; Chun L Zhang; Lei Ni; Cheng J Ma; Ying Zhang; Xiao Y Wu; Antwan N Atia; Zhi Q Yao; Jonathan P Moorman
Journal:  Viral Immunol       Date:  2010-10       Impact factor: 2.257

Review 3.  Hepatitis C virus and ethanol alter antigen presentation in liver cells.

Authors:  Natalia A Osna
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

4.  Acetaldehyde accelerates HCV-induced impairment of innate immunity by suppressing methylation reactions in liver cells.

Authors:  Murali Ganesan; Jinjin Zhang; Tatiana Bronich; Larisa I Poluektova; Terrence M Donohue; Dean J Tuma; Kusum K Kharbanda; Natalia A Osna
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-08-06       Impact factor: 4.052

5.  The role of hepatic expression of STAT1, SOCS3 and PIAS1 in the response of chronic hepatitis C patients to therapy.

Authors:  Sherif El-Saadany; Dina H Ziada; Hanan El Bassat; Wael Farrag; Hesham El-Serogy; Manal Eid; Manal Abdallah; Medhat Ghazy; Hoda A Salem
Journal:  Can J Gastroenterol       Date:  2013-02       Impact factor: 3.522

6.  Interferon alpha regulates MAPK and STAT1 pathways in human hepatoma cells.

Authors:  Lan-Juan Zhao; Xian Hua; Sheng-Fei He; Hao Ren; Zhong-Tian Qi
Journal:  Virol J       Date:  2011-04-06       Impact factor: 4.099

7.  PCBP2 enhances the antiviral activity of IFN-α against HCV by stabilizing the mRNA of STAT1 and STAT2.

Authors:  Zhongshuai Xin; Wei Han; Zhiqiang Zhao; Qing Xia; Bin Yin; Jiangang Yuan; Xiaozhong Peng
Journal:  PLoS One       Date:  2011-10-11       Impact factor: 3.240

Review 8.  STAT1 and pathogens, not a friendly relationship.

Authors:  Imen Najjar; Remi Fagard
Journal:  Biochimie       Date:  2010-02-13       Impact factor: 4.079

9.  Interferon-α-Enhanced CD100/Plexin-B1/B2 Interactions Promote Natural Killer Cell Functions in Patients with Chronic Hepatitis C Virus Infection.

Authors:  Yu He; Yonghong Guo; Chao Fan; Yingfeng Lei; Yun Zhou; Mingjie Zhang; Chuantao Ye; Guangxi Ji; Li Ma; Jianqi Lian; Jonathan P Moorman; Zhi Q Yao; Jiuping Wang; Chunqiu Hao; Ying Zhang; Zhansheng Jia
Journal:  Front Immunol       Date:  2017-11-03       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.